On August 10, CSPC PHARMA rose 4.43% in regular trading, trading at HK$8.98 per share, with turnover of HK$76.02 million. The rally was driven by a cluster of positive developments centered on its deepening strategic partnership with AstraZeneca.

On August 5, CSPC PHARMA announced it received a US$10 million milestone payment from AstraZeneca following the exercise of a license option for one pre-clinical candidate program under their strategic R&D collaboration agreement originally disclosed in June 2025. The same day, the two parties signed a joint venture contract to establish a new-generation biologics manufacturing facility in Shijiazhuang, China, with CSPC holding 51% and AstraZeneca holding 49%. Additionally, on August 4, the company's co-developed anituomab plus docetaxel neoadjuvant therapy new drug application was accepted by China's NMPA and granted priority review status.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)